News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shire plc: Statement re: AbbVie (ABBV) Announcement


7/8/2014 9:35:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Shire plc (“Shire” or the “Company”) (LSE: SHP, NASDAQ: SHPG) notes the announcement by AbbVie Inc. (“AbbVie”) of a revised conditional non-binding proposal for a cash and share offer for Shire, comprising £22.44 in cash and 0.8568 AbbVie shares per Shire share.

Shire confirms that AbbVie did not make the revised proposal to Shire before the announcement.

The Board of Shire will meet to consider the proposal and a further announcement will be made in due course.

Shareholders are strongly advised to take no action in relation to the AbbVie proposal. There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives. We provide treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

Shire’s product sales from continuing operations have increased from US$2,754 million in the financial year to 31 December 2008 to US$4,757 million in the financial year to 31 December 2013, representing a five-year compound annual growth rate of 11.6%. Shire’s Non GAAP diluted earnings per ADS have increased from US$3.86 in the financial year to 31 December 2008 to US$7.66 in the financial year to 31 December 2013, representing a five-year compound annual growth rate of 14.7%. Shire’s US GAAP diluted earnings per ADS have increased from US$0.86 in the financial year to 31 December 2008 to US$3.53 in the financial year to 31 December 2013, representing a five-year compound annual growth rate of 32.7%.

www.Shire.com

CONTACTS

Shire Stephanie Fagan +1 201 572 9581

FTI Consulting (Media Adviser to the Company)
Andrew Lorenz (London) +44 77 7564 1807
Ben Atwell (London) +44 20 3727 1000
David B. Roady (New York) +1 212 850 5600
Robert Stanislaro (New York) +1 212 850 5600


Citi (Financial Adviser to the Company)
Christopher Hite +1 212 816 1818
Jan Skarbek +44 20 7986 4000

Deutsche Bank (Financial Adviser to the Company)
Nick Bowers (Corporate Broking) +44 20 7545 8000
Ben Lawrence (Corporate Broking)

Evercore (Financial Adviser to the Company)
Francois Maisonrouge +44 20 7653 6000
Edward Banks

Goldman Sachs (Financial Adviser to the Company)
Anthony Gutman +44 20 7774 1000
Raj Shah

Morgan Stanley (Financial Adviser to the Company)
Michele Colocci +44 20 7425 8000
Colm Donlon
Peter Moorhouse (Corporate Broking)

A copy of this announcement will be available at www.Shire.com. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES